The US Centers for Medicare and Medicaid Services (CMS) is optimistic that a new voluntary program it expects to launch in 2025 that could help pave the way for broader access to expensive cell and gene therapies under Medicaid, while also saving the government money.
Center for Medicare and Medicaid Innovation (CMMI) deputy director Ellen Lukens discussed some of the goals of the program – and some of the barriers that need to be overcome – during a